drug_type
RELEVANT_DRUG
intervention_type
Bispecific monoclonal antibody (biologic)
drug_description
Intravenous bispecific monoclonal antibody (anti-BCMA × anti-CD3) that redirects T cells to kill BCMA-expressing malignant plasma cells; also known as REGN5458.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Linvoseltamab is an intravenous bispecific monoclonal antibody (anti-BCMA × anti-CD3) that simultaneously binds BCMA on malignant plasma cells and CD3 on T cells, forming an immunologic synapse that activates and redirects T cells to kill BCMA-expressing myeloma cells through cytotoxic granule release and cytokine-mediated mechanisms.
drug_name
Linvoseltamab
nct_id_drug_ref
NCT05730036